"Cardiovascular Research"

During the past decade, Victoria Heart Institute Foundation conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 8 clinical trials were completed, i.e. on average, 88.9% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Victoria Heart Institute Foundation" #1 sponsor was "Boehringer Ingelheim" with 3 trials, followed by "Sir Mortimer B. Davis - Jewish General Hospital" with 3 trials sponsored, "Biosensors Europe SA" with 2 trials sponsored, "On-X Life Technologies, Inc." with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Victoria Heart Institute Foundation" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 4 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Sigvaris Corporation" with 3 trials as a collaborator, "Heart and Stroke Foundation of Canada" with 2 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Victoria Heart Institute Foundation" are "Heart Failure" (5 trials), "Myocardial Infarction" (5 trials), "Acute Coronary Syndrome" (4 trials), "Cardiovascular Disease" (3 trials) and "Atherosclerosis" (2 trials). Many other conditions were trialed in "Victoria Heart Institute Foundation" in a lesser frequency.

Most popular intervention types in "Victoria Heart Institute Foundation" are "Drug" (18 trials), "Device" (6 trials), "Procedure" (3 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Empagliflozin" (3 trials), "bococizumab (PF-04950615)" (2 trials), "Antiplatelet Drug" (1 trials) and "Apixaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "Victoria Heart Institute Foundation" are 31 trials for "All" genders.

Currently, there are NaN active trials in "Victoria Heart Institute Foundation". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Victoria Heart Institute Foundation, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Victoria Heart Institute Foundation, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".